Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Acquires 2,000 Shares

Greenwich LifeSciences, Inc. (NASDAQ:GLSIGet Free Report) CEO Snehal Patel bought 2,000 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were bought at an average price of $11.97 per share, with a total value of $23,940.00. Following the completion of the transaction, the chief executive officer now owns 5,543,702 shares of the company’s stock, valued at $66,358,112.94. The trade was a 0.04 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Snehal Patel also recently made the following trade(s):

  • On Monday, December 30th, Snehal Patel acquired 3,200 shares of Greenwich LifeSciences stock. The shares were bought at an average price of $11.12 per share, for a total transaction of $35,584.00.

Greenwich LifeSciences Stock Performance

Shares of NASDAQ:GLSI opened at $13.11 on Tuesday. The firm has a fifty day moving average of $13.18 and a 200 day moving average of $14.15. Greenwich LifeSciences, Inc. has a 52-week low of $8.00 and a 52-week high of $21.44. The firm has a market capitalization of $172.33 million, a PE ratio of -16.39 and a beta of 1.66.

Hedge Funds Weigh In On Greenwich LifeSciences

Hedge funds and other institutional investors have recently modified their holdings of the company. Rhumbline Advisers purchased a new position in shares of Greenwich LifeSciences during the 2nd quarter valued at about $117,000. Barclays PLC grew its position in Greenwich LifeSciences by 323.3% during the third quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after acquiring an additional 6,538 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Greenwich LifeSciences during the second quarter worth approximately $264,000. Garden State Investment Advisory Services LLC bought a new stake in shares of Greenwich LifeSciences in the 3rd quarter worth approximately $253,000. Finally, State Street Corp boosted its stake in shares of Greenwich LifeSciences by 4.4% in the 3rd quarter. State Street Corp now owns 71,408 shares of the company’s stock valued at $1,026,000 after purchasing an additional 3,005 shares in the last quarter. 4.16% of the stock is currently owned by hedge funds and other institutional investors.

About Greenwich LifeSciences

(Get Free Report)

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

See Also

Insider Buying and Selling by Quarter for Greenwich LifeSciences (NASDAQ:GLSI)

Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.